Volufiline 92% + Pal-Isoleucine 1% Plumping Anhydrous Serum

There is a particular kind of The Ordinary launch that exists mostly as a public science experiment. This is one of them. Volufiline has been quietly turning up in the middle of other brands' ingredient lists for more than a decade — usually at two or three percent, usually unnamed on the front of the bottle, usually supporting a more marketable hero like a peptide or a retinoid. Deciem's move here is to strip almost everything else away and let you see what a bottle of essentially just Volufiline does to your face over a couple of months. The 92% on the label is not really a concentration in the normal sense; it's closer to saying this formula is Volufiline and a few structural extras, full stop.

Open the dropper and the liquid is clear, slightly viscous, and scentless. It is technically an oil — the entire base is hydrogenated polyisobutene, a highly refined synthetic hydrocarbon that sits somewhere between squalane and a light silicone in feel — but it is noticeably less heavy than a traditional plant oil. Rhus succedanea wax gives it a touch of body so it doesn't run off the fingertips, caprylyl glycol and polyglyceryl-3 stearate help distribute the Anemarrhena extract through the oil phase, and tocopherol handles the oxidation housekeeping. That is the whole deck. No water, no preservatives, no actives competing for attention.

That minimalism is the point. Volufiline is a finicky ingredient to formulate with: it is oil-soluble, the extract it carries can oxidize, and emulsifying it into a traditional cream usually means cutting the load to a few percent and hoping it survives contact with water and surfactants. Going fully anhydrous sidesteps all of that. The active reaches skin in the form the manufacturer originally delivered it in, at a load the manufacturer's own research never quite tested, inside a vehicle that is itself an occlusive. If you are the sort of person who likes to know exactly what is doing the work, it is hard to argue with the honesty of the approach.

The case for Volufiline is that sarsasapogenin from Anemarrhena root can encourage lipid accumulation in isolated fat cells, which in a facial skin context is supposed to translate to a subtly plumper appearance where age-related volume loss has thinned the soft tissue. The case against it is that most of the supporting data is from the ingredient maker, sample sizes are small, and the visible effects in those studies are modest — millimeters and percentage changes, not the dramatic lift of a procedure. Both things can be true at once. Treating this serum as a long, slow experiment in lipid support is probably the right mental model; treating it as a filler replacement will set you up for disappointment.

In daily use it behaves well. Three or four drops pressed into cheeks and the upper neck after a hydrating serum sink in within a minute, leaving a satin finish rather than the greasy film a plant oil often produces. Layering sunscreen or makeup on top is uneventful if you don't overapply; go heavy and you'll get some slip. The first week's improvement is almost entirely the occlusion story — skin looks smoother and better hydrated because it is, and that by itself is a real visual upgrade for drier complexions. Whatever genuine plumping Volufiline is going to do on a given face tends to show up later, around the two-to-three-month mark of twice-daily use, and it is always a quiet change rather than a loud one.

Palmitoyl isoleucine at one percent is the other ingredient Deciem wants you to notice. It is a lipoamino acid rather than a signal peptide, which means it does not behave like a matrixyl or an argireline — it sits in the lipid matrix and is positioned as a supporting conditioner for the same adipocyte story. The honest read is that it is there partly for mechanism and partly for label: pairing Volufiline with a named secondary active is a more compelling product than Volufiline alone, even if the one percent level is modest. It does not hurt the formula and it plausibly helps, which is a reasonable bar to clear.

Where this serum shows its limits is in scope. The 15 mL bottle is small for twice-daily use on the full face and neck, and realistically you'll go through it in six to eight weeks. It is not a moisturizer on its own — skin that needs humectant hydration still needs a water-phase product underneath. And the subtlety of the effect means it is best thought of as an add-on to a well-built routine, not a centerpiece. If your routine is already doing the work of sunscreen, retinoids, and barrier support, this can layer in as a slow-burn plumping assist. If your routine is missing those fundamentals, spend the twenty-one dollars there first.

At the price, though, it is one of the easiest ingredient experiments to justify. Volufiline-forward products elsewhere typically sit north of forty dollars and deliver the active at a fraction of the load. If you wanted to know what Volufiline does to your face without any other variables in the way, this is now the cheapest and cleanest way to find out — which is, as always, the specific kind of useful The Ordinary is good at.

Formula

The Science

The Volufiline claim rests on a small body of work around sarsasapogenin, a steroidal saponin found in Anemarrhena asphodeloides. In vitro studies by the ingredient's maker, Sederma, reported increased lipid accumulation in 3T3-L1 preadipocyte cultures exposed to the active, and a 56-day in vivo study reported modest gains in cheek volume measured by silicone replica and 3D imaging. These findings are genuinely interesting at the cell-biology level — saponins as lipogenic signals are not a common formulation story — but the data is small-scale, largely manufacturer-funded, and has not been widely replicated in independent peer-reviewed literature. What this anhydrous formula does well is remove confounders: by eliminating water, surfactants, and secondary actives, it delivers the Anemarrhena extract in essentially the same lipid carrier used in the original studies, at a far higher load. Whether that translates to a bigger effect on human facial skin is an open question — dose-response in the published work plateaus well below the levels used here. Palmitoyl isoleucine is the secondary story: a lipoamino acid designed to conditioner-like sit in the stratum corneum lipid phase, with the mechanistic rationale of supporting the same adipocyte biology rather than acting through the classic cell-signaling pathway that peptides like Matrixyl use. Evidence here is sparser still and mostly mechanistic. The safest read on the science is that the individual components have plausible mechanisms and early-stage evidence, the formulation is the cleanest possible way to test them on skin, and users should calibrate expectations to "subtle surface plumping over months" rather than "visible volume restoration."

Dermatologist Perspective

Dermatologists tend to place ingredients like Volufiline in the category of promising-but-unproven adjuncts — interesting enough to recommend as a low-risk addition to a routine, not strong enough to replace the building blocks of an evidence-based aging strategy. The foundational recommendations for age-related volume loss and skin thinning are still daily broad-spectrum sunscreen, a tolerated retinoid, and barrier-supporting moisturizers; anything beyond that is a secondary layer. Where a product like this fits comfortably is as that secondary layer in an already complete routine, particularly for patients who want to try a new active without taking on additional irritation risk. Board-certified dermatologists frequently note that fragrance-free, short ingredient lists are an asset in reactive or menopausal skin — categories that overlap heavily with the "loss of volume" audience this serum targets. The clinical expectation should stay realistic: any visible plumping is likely to be modest, gradual, and additive to what the sunscreen and retinoid are already doing, not a substitute for them.

Guidance

Volufiline has been floating around indie and K-beauty formulations since Sederma introduced it over a decade ago, usually as a quiet supporting ingredient. The Ordinary's move here — stripping the formula to almost nothing but Volufiline itself — is classic Deciem: take a trademarked active that has always been hidden, put it on the label at an almost absurd concentration, and let consumers decide.

About The Ordinary Established Brand (5–20 years)

The Ordinary launched in 2016 under Deciem's mandate to deliver studied actives at cost-plus pricing. Over a decade in, its product range is widely recommended by dermatologists on social media and has become a reference point for ingredient-first formulating, though individual launches still vary in how much independent clinical backing they carry.

Brand founded: 2016 · Product launched: 2025

Myth vs. Reality

Myth

Volufiline literally grows new fat cells in your face to plump it.

Reality

In vitro studies show Volufiline can stimulate lipid accumulation in isolated adipocytes, but the real-world effect on adult human facial fat pads is modest and not equivalent to a volumizing procedure. Treat any plumping you see here as surface smoothing and lipid replenishment, not true volume restoration.

Myth

Because it's 92% Volufiline, it must work 20x better than a 5% Volufiline product.

Reality

Dose-response for this ingredient plateaus well below 92%, and most published work uses 2–5% levels. The high number is striking on the label but the practical ceiling of the effect is likely similar to well-formulated competitors.

FAQ

Common Praise

"Lightweight oil feel despite high polyisobutene load"

"Short, fragrance-free ingredient list"

"Fair price point for a Volufiline-forward product"

Common Complaints

"Small 15 mL size relative to twice-daily use"

"Plumping effect is subtle at best"

"Feels slippery under makeup if over-applied"

Appears In

best the ordinary for aging best plumping serum best anhydrous serum best budget anti aging serum

Related Conditions

aging dryness

Related Ingredients

peptides hyaluronic acid squalane ceramides